Biocon Finalizes Merger Between Covidshield And Biologics Business

Biocon Biologics Will Have Access To 100 Million Vaccine Doses Each Year

 
• By Chloe Kent
  
Adar Poonawalla and Kiran Mazumdar-Shaw shake hands
The merger is expected to combine Serum's supply chain with Biocon's marketing prowess • Source: Company
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business